Zobrazeno 1 - 10
of 433
pro vyhledávání: '"Sherwood L. Gorbach"'
Fidaxomicin versus Vancomycin in the Treatment of Clostridium difficile Infection: Canadian Outcomes
Autor:
Christine Lee, Thomas J. Louie, Karl Weiss, Louis Valiquette, Marvin Gerson, Wendy Arnott, Sherwood L. Gorbach
Publikováno v:
Canadian Journal of Infectious Diseases and Medical Microbiology, Vol 2016 (2016)
Background. This analysis examined the efficacy of fidaxomicin versus vancomycin in 406 Canadian patients with Clostridium difficile infection (CDI), based on data from 2 randomized, clinical trials. Methods. Patients received fidaxomicin or vancomyc
Externí odkaz:
https://doaj.org/article/0e920db448264de89e2752b706572e41
Autor:
Sherwood L. Gorbach
Publikováno v:
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 73(4)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ec0e04f921d5457687a6c9e750fce928
https://pubmed.ncbi.nlm.nih.gov/33508101
https://pubmed.ncbi.nlm.nih.gov/33508101
Autor:
Sherwood L. Gorbach, Barbara D. Alexander, Natalya Broyde, Michele I. Morris, Patrick J. Stiff, Ajay K. Nooka, Michael J Dugan, Pamela Sears, Henry Holland, Javier A. Adachi, Drew J. Winston, Erik R. Dubberke, Kevin S. Gregg, Kathleen M. Mullane, Steven A. Pergam
Publikováno v:
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
Patients undergoing hematopoietic stem cell transplantation are at elevated risk for development of Clostridium difficile–associated diarrhea (CDAD). Fidaxomicin may have a role in the prevention of CDAD in these patients.
Background Clostridi
Background Clostridi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64d5b203220414e74934ce2229a0024c
https://doi.org/10.1093/cid/ciy484
https://doi.org/10.1093/cid/ciy484
Publikováno v:
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 36:1281-1289
In recent years, Clostridium difficile infection (CDI) has become a global public health threat associated with increased morbidity, mortality, and economic burden, all of which are exacerbated with disease recurrence. Current guidelines informing tr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b932477b2160c9db48758aa2d8bb4584
https://doi.org/10.1002/phar.1863
https://doi.org/10.1002/phar.1863
Autor:
Sherwood L. Gorbach
Publikováno v:
Anaerobe. 67:102332
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4e604b39e957d711f406e3d667ecab91
https://doi.org/10.1016/j.anaerobe.2021.102332
https://doi.org/10.1016/j.anaerobe.2021.102332
Publikováno v:
Attachment of Organisms to the Gut Mucosa ISBN: 9781351069960
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4849402dd0b1fc1dae9b37c65bce1b6a
https://doi.org/10.1201/9781351069960-11
https://doi.org/10.1201/9781351069960-11
Publikováno v:
Clinical Insights: Probiotics, Prebiotics and Gut Health. :119-139
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::44a3217950eb4fc40e85e26f89309d04
https://doi.org/10.2217/ebo.13.281
https://doi.org/10.2217/ebo.13.281
Autor:
Sherwood L. Gorbach, Oliver A. Cornely, Yin Kean, Mark A. Miller, Kathleen M. Mullane, Bruno Fantin
Publikováno v:
Journal of Clinical Oncology. 31:2493-2499
Purpose Patients with cancer are at increased risk for Clostridium difficile–associated diarrhea (CDAD). Little is known about treatment response. Patients and Methods Two double-blind trials randomly allocated 1,105 patients with CDAD to fidaxomic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::92bf85a8ef88d01a034637ea87a12dcc
https://doi.org/10.1200/jco.2012.45.5899
https://doi.org/10.1200/jco.2012.45.5899
Publikováno v:
Annals of the New York Academy of Sciences. 1291:33-41
Clostridium difficile infection, also known as C. difficile-associated diarrhea (CDAD), is the most common cause of nosocomial diarrhea, typically initiated by the use of broad-spectrum antibiotics that disrupt gut flora, thereby allowing C. difficil
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e9ddd9552e4000675961fe6731539bde
https://doi.org/10.1111/nyas.12135
https://doi.org/10.1111/nyas.12135
Autor:
Thomas J. Louie, Yoav Golan, Oliver A. Cornely, Derrick W. Crook, Mark A. Miller, Michelle A. Josephson, Kathleen M. Mullane, Sherwood L. Gorbach
Publikováno v:
American Journal of Nephrology. 38:1-11
Background/Aims: Patients with chronic kidney disease (CKD) have increased risk for Clostridium difficile infection (CDI) and for subsequent mortality. We determined the effect of CKD on response to treatment for CDI. Methods: This is a post hoc anal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ffd483827bb64cdaabf34211e13999c2
https://doi.org/10.1159/000351757
https://doi.org/10.1159/000351757